Next Step Towards Artificial Intelligence in Transplant Care as CareDx Adds iBox Technology

Molecular diagnostics company, CareDx, Inc. is to partner Cibiltech, a French MedTech company that develops AI-based products for predictive medicine, to commercialize Predigraft. Predigraft is a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss


CareDx is focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients.

The company’s Predigraft was developed from Cibiltech’s proprietary software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients.

Under the new agreement, CareDx holds the exclusive rights to commercialize Predigraft in the US and CareDx becomes a minority equity owner of Cibiltech. The companies have also agreed to collaborate to advance the development of artificial intelligence in transplant care. CareDx and Cibiltech will be sharing demonstrations of iBox at the American Transplant Congress June 1-4, 2019 in Boston.

Company comments

“We are delighted to collaborate with CareDx as it is a very promising step to bring years of work on artificial intelligence from the Paris Transplant Group to transplant patients. Our technology has been selected by numerous peer reviewed publications, and we believe that the team at CareDx is a great partner to make this available to the field of transplantation,” said Alexandre Loupy, MD, iBox inventor and Cibiltech founding partner.

“CareDx has taken another step towards bringing big data solutions to transplant patients,” said Peter Maag, CEO of CareDx. “With OTTR providing data infrastructure and with iBox providing prognostic information, we are beginning to assemble new and important solutions for caregivers that are based on artificial intelligence.”

Clinician comments

“I see incredible value in using prognostic data alongside a measure of organ injury from non-invasive biomarkers such as AlloSure,” said Gaurav Gupta, MD, Virginia Commonwealth University. “This can give me insights that shape the care I give to my transplant patients.”

Source: Globe Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *